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We have shown previously that diabetes causes increases in retinal arginase activity
that are associated with impairment of endothelial cell (EC)-dependent vasodilation and
increased formation of the peroxynitrite biomarker nitrotyrosine. Arginase blockade normal-
izes vasodilation responses and reduces nitrotyrosine formation, suggesting that overactive
arginase contributes to diabetic retinopathy by reducing NO and increasing oxidative stress.
We tested this hypothesis by studies in streptozotocin-induced diabetic mice and high glu-
cose (HG) treated retinal ECs. Our results show that arginase activity is increased in both
diabetic retinas and HG-treated retinal ECs as compared with the controls. Western blot
shows that both arginase isoforms are present in retinal vessels and ECs and arginase I is
increased in the diabetic vessels and HG-treated retinal ECs. Nitrate/nitrite levels are signif-
icantly increased in diabetic retinas, indicating an increase in total NO products. However,
levels of nitrite, an indicator of bioavailable NO, are reduced by diabetes. Imaging analy-
sis of NO formation in retinal sections confirmed decreases in NO formation in diabetic
retinas. The decrease in NO is accompanied by increased O.2
− formation and increased
leukocyte attachment in retinal vessels. Studies in knockout mice show that arginase gene
deletion enhances NO formation, reduces O.2
− and prevents leukostasis in the diabetic
retinas. HG treatment of retinal ECs also reduces NO release, increases oxidative stress,
increases ICAM-1, and induces EC death. Arginase inhibitor treatment reverses these
effects. In conclusion, diabetes- and HG-induced signs of retinal vascular activation and
injury are associated with increased arginase activity and expression, decreased bioavail-
able NO, and increased O.2
− formation. Blockade of the arginase pathway prevents these
alterations, suggesting a primary role of arginase in the pathophysiological process.
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INTRODUCTION
Diabetic retinopathy, a microvascular complication of diabetes,
is the leading cause of blindness in adults of working age (1).
Diabetes-induced retinal vascular alterations include leukosta-
sis, increased permeability, pericyte loss, appearance of acellular
capillaries, and pathological angiogenesis (2, 3). The underlying
mechanisms are still unclear. However evidence is accumulating
that diabetes-induced retinal vascular dysfunction is associated
with hyperglycemia-induced increases in formation of superox-
ide and peroxynitrite (4–8). Studies have shown that diabetes and
high glucose (HG)-induced increases in oxidative and nitrosative
stress are accompanied by increases in expression and activity of
both endothelial nitric oxide synthase (eNOS) and inducible nitric
oxide synthase (iNOS) and that inhibiting NOS activity reduces
oxidative and nitrosative stress and prevents early signs of dia-
betic retinopathy (8–12). However, in spite of the well established
link between nitrosative stress and vascular injury in models of
diabetes, other work has shown that diabetes impairs ocular hemo-
dynamics by reducing the bioavailability of nitric oxide (NO) (13).
NO plays a critical role in maintaining proper tissue blood flow
and perfusion, blocking platelet activation and leukocyte adhe-
sion, preventing smooth muscle cell proliferation, and enhancing
endothelial cell (EC) survival (14). NO is generated by NO syn-
thase (NOS) from its substrate l-arginine. Acute administration
of l-arginine has been shown to increase NO synthesis and restore
endothelial-dependent vasodilation in several diseases character-
ized by vascular dysfunction, including diabetes, hypertension,
and heart failure (15, 16), suggesting that decreased l-arginine
availability is pivotal to their pathogenesis (17, 18).
Arginase, an enzyme of the urea cycle, uses l-arginine as sub-
strate to produce urea and ornithine. Studies have shown that
excessive activity of arginase limits the supply of l-arginine needed
for proper NOS function, which will cause uncoupling of the NOS
dimer. Uncoupled NOS will use more molecular oxygen to pro-
duce superoxide instead of NO. Superoxide will react rapidly with
any available NO to produce the highly toxic and proinflammatory
oxidant peroxynitrite. This mechanism has been linked to vascular
dysfunction in many diseases including diabetes (19, 20). More-
over, angiotensin II, which is upregulated in the diabetic retina,
has been shown to increase arginase expression and activity by a
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mechanism involving activation of P38 MAP kinase/Rho kinase
pathway (21).
In a model of endotoxin-induced retinal inflammation, we
have shown that elevated arginase activity and expression is corre-
lated with decreases in NO formation, increased cytokine release
and retinal inflammation (22). Our studies in rodent models
of diabetes have shown that impairment of retinal endothelial-
dependent vasodilation is mediated by increases in arginase
expression/activity (23). In this study, we hypothesized that
increases in arginase expression/activity have a role in diabetes-
induced retinal vascular activation/injury via a mechanisms
involving decreases in bioavailable NO.
MATERIALS AND METHODS
TREATMENT OF MICE
All procedures with animals were performed in accordance with
the NIH Guide for the Care and Use of Laboratory Animals and
were approved by the institutional animal care and use committee
(Animal Welfare Assurance no. A3307-01). Experiments were per-
formed with double knockout mice lacking one copy of arginase I
and both copies of II (AI+/−AII−/−) (24). Deletion of both copies
of arginase I is lethal around 10 days postnatal. The knockout mice
were provided by Dr. Steven Cederbaum. C57BL6J mice were used
as controls. Diabetes was induced by repeated injection (up to
four times) of streptozotocin [STZ, 65 mg/kg, dissolved in 0.1 M
sodium citrate buffer (pH 4.5), i.p.], once every other day until
diabetes was established. Mice with glucose level over 350 mg/dl
as determined by a blood glucose meter were considered diabetic.
Diabetic and age-matched control mice were used for experiments
after 2 months of diabetes.
CELL CULTURE
Bovine retinal ECs (passages 5–9) were incubated in the medium
(M199+ 0.2%FBS+ 50µM l-arginine) containing 5.5 mM d-
glucose (NG), 25 mM d-glucose (HG) for 1–3 days. For treatment
with the arginase inhibitors [S-(2-boronoethyl)-l-cysteine (BEC),
2(S)-amino-6-boronohexanoic acid (ABH)], cells were treated
with BEC (10µM) or ABH (100µM) together with HG.
RETINAL VESSEL ISOLATION
Retinas were dissected and placed in water on ice for 1 h followed
by treatment with Deoxyribonuclease I (116 U/ml, 25–30 min,
Worthington Biochemical Corp., Lakewood, NJ, USA). Vessels
were rinsed to remove contaminating neurons and glia and then
homogenized. Protein was extracted by RIPA lysis buffer (Milli-
pore, Billerica, MA, USA). The supernatant (each containing 10µg
protein) was mixed with 4× loading buffer. After boiling, the sam-
ples were analyzed by western blot as described below. Vessel purity
was verified by microscopic examination of the vessel prepara-
tions. Retinal vessels from six different animals were combined for
each determination and five different replications were prepared
for both diabetic and control mice.
WESTERN BLOT
Retinas or ECs were homogenized in a RIPA Lysis Buffer (Mil-
lipore) supplied with phosphatase inhibitor cocktail (Roche),
1 mM phenyl methyl sulfonyl fluoride, and protease inhibitor
cocktail (Sigma-Aldrich). Twenty micrograms protein samples
were subjected to 10% SDS polyacrylamide gel electrophore-
sis (SDS-PAGE). Proteins were transferred onto a nitrocellulose
membrane and the membrane was blocked (5% milk) and incu-
bated with primary antibodies against arginase I (1:500, Santacruz
Biotech), arginase II (1:500, Santacruz Biotech), intercellular adhe-
sion molecule 1 (ICAM-1) (1:500, Santacruz Biotech), actin
(1:2000, Sigma-Aldrich), and β-tubulin (1:2000, Sigma-Aldrich),
followed by horseradish peroxidase-conjugated secondary anti-
body (1:2000, GE Healthcare Bio-Sciences). Immunoreactive pro-
teins were detected using the enhanced chemiluminescence (ECL)
system (GE Healthcare Bio-Sciences).
ARGINASE ACTIVITY
Retinas or ECs were homogenized in ice-cold lysis buffer (50 mM
Tris-HCl, 0.1 mM EDTA, and EGTA, pH 7.5) containing pro-
tease inhibitors with a pestle. The homogenate was centrifuged
at 14,000 g for 20 min and the supernatant was removed for
enzyme assay. Arginase activity was assayed as previously described
(19). Briefly, the enzyme was activated by heating the lysate at
56°C in 25 mM Tris buffer (pH 7.4) containing 5 mM MnCl2. l-
Arginine hydrolysis was then conducted by incubating 50µl of
the activated lysate with 50µl of 0.5 M l-arginine (pH 9.7) at
37°C for 60 min. The reaction was stopped in acid medium. The
concentration of urea, which is the end product of l-arginine
hydrolysis by arginase, was determined after adding 25µl of 9%
α-isonitrosopropiophenone. Protein concentration in the lysates
was determined by a BCA assay (Pierce Biotechnology). Arginase
activity was calculated as mmol urea/mg protein and as percent of
control.
IMMUNOFLUORESCENCE
Eyes were removed, fixed in 4% paraformaldehyde (overnight,
4°C), washed in PBS and retinas were isolated and cryoprotected
in 30% sucrose. Frozen sections (10µM) were permeabilized in
1% Triton (10 min) and blocked in 10% normal goat serum con-
taining 1% BSA (1 h). Sections were incubated overnight at 4°C
in primary antibodies (monoclonal anti-arginase I, 1:200, BD
Biosciences; polyclonal anti-arginase II, 1:200, Santacruz Biotech-
nology; polyclonal CRALBP cellular retinaldehyde binding pro-
tein, 1:200, Santacruz Biotechnology) followed by reaction with
fluorescein or Texas red conjugated secondary antibodies (Mol-
ecular Probes), PBS rinse and mounted with Vectashield (Vector
Laboratories).
NITRITE AND NITRATE FORMATION
For in vivo studies retinas from WT mice with normal glucose
(Con), HG (Db), or from AI+/−AII−/− mice with HG (Db-Ko)
were homogenized in PBS and centrifuged at 14000 rpm for 10 min
at 4°C and supernatants were collected. The level of nitrite in the
supernatants was analyzed using NO-specific chemiluminescence.
In brief, samples containing nitrite were refluxed in glacial acetic
acid containing sodium iodide. Nitrite is quantitatively reduced to
NO under these conditions, which can be quantified by a chemi-
luminescence detector after reaction with ozone in a Seivers NO
analyzer (NOA 280i, GE Analytical Instruments, Boulder, CO,
USA). To measure the total level of nitrite plus nitrate, super-
natants were incubated with PBS containing nitrate reductase
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(0.25 U/ml), NADPH (13µg/ml), and FAD-Na2 (4µg/ml) at 30°C
for 1 h to reduce nitrate to nitrite. Then the level of nitrite was
analyzed using NO-specific chemiluminescence. Protein concen-
tration in the supernatant was determined by BCA assay. The level
of nitrite or nitrite plus nitrate was normalized to the protein
concentration in the supernatant and calculated as percentage of
control. Wild type mice with normal glucose were used as refer-
ence. For in vitro studies, retinal ECs were treated with 5.5 mM
normal glucose (NG), 25 mM HG, or 35 mM glucose for 24 h in
M199 medium containing 0.2%FBS and 50µM l-arginine. Nitrite
level in the conditioned media was measured as described in the
above procedures for retinal lysates.
NO FORMATION IN SITU
The NO fluorescent indicator 4,5-diaminofluorescein diacetate
(DAF-2 DA, Calbiochem) was used to assess production of NO
in retinal tissue sections. In presence of oxygen, DAF-2 reacts with
NO to yield the highly fluorescent product triazolofluorescein,
which is monitored using excitation and emission wavelengths of
485 and 538 nm, respectively. Unfixed fresh retinal frozen sections
from each group were reacted with DAF-2 DA (10µM, 15 min in
the dark at 37°C). One set was pretreated with the NOS inhibitor
L-NAME (1 mM). The slides were washed with Hepes solution
(10 mM), covered and a series of nine images from each slide
were taken by using AxioVision Imaging System (Zeiss). Fluo-
rescence intensity was quantified using MetaMorph Microscopy
Image Analysis Software (Molecular Devices).
DIHYDROETHIDIUM ASSAY FOR SUPEROXIDE FORMATION
To evaluate production of superoxide in situ the oxidative fluores-
cent dye dihydroethidium (DHE) was used as described previously
(25, 26). DHE is freely permeable to cells and in the presence of
O.−2 is oxidized to ethidium bromide which binds to DNA and
fluoresces red. The images were analyzed for reaction intensity by
using the MetaMorph Image System (Molecular Devices).
LEUKOCYTE ADHESION
Retinal leukostasis was assayed by labeling the adherent leuko-
cytes using Concanavalin A (Vector Laboratories). This method
has been described previously (26).
TUNEL ASSAY
Endothelial cell death was studied using TUNEL (Terminal
deoxynucleotidyl transferase dUTP nick end labeling) assay using
Fluorescein in situ cell death detection kit (Millipore) according to
the manufacturer’s protocol. Fluorescent images were taken and
the number of TUNEL positive cells was quantified manually.
STATISTICAL ANALYSIS
Data are presented as mean± SEM. Group differences were eval-
uated by using one way analysis of variance followed by Tukey’s
post hoc test for statistical analysis. p< 0.05 was considered sig-
nificant. Animal studies were performed in groups of 6–18 mice.
Tissue culture studies were performed in groups of four to eight
cultures and each experiment was repeated in at least twice for
cells derived from different primary isolates.
RESULTS
ARGINASE ACTIVITY AND EXPRESSION ARE INCREASED BY DIABETES
AND HIGH GLUCOSE
We first examined the effects of diabetes on arginase activity
in retinas from STZ-induced diabetic and age-matched control
mice (8 weeks). Immunofluorescence analysis showed that both
arginase isoforms are expressed in the mouse retina (Figure 1A).
The two isoforms differed in their distribution pattern. Arginase
I was strongly expressed in cells within the ganglion cell layer and
inner nuclear layer and in cells that resemble Müller glia (arrow-
heads). Localization of arginase I in Müller glia was confirmed by
double labeling for arginase I and the Müller cell marker cellular
retinaldehyde binding protein (CRALBP; Figure 1B). Retinal ves-
sels in all groups are also labeled due to cross reactivity between
mouse vascular proteins and the anti-mouse secondary antibody.
Control studies performed in the AI+/−AII−/− mice showed low
levels of arginase I immunoreactivity, consistent with hemizy-
gous deletion of the arginase I gene. Arginase II was strongly
expressed in cells of the inner nuclear layer cells as well as
in cells in the nerve fiber and inner plexiform layers. Sections
from the AI+/−AII−/− mice were negative for arginase II (data
not shown). Measurement of arginase activity in retinal tissue
extracts using an assay for urea produced by l-arginine hydrol-
ysis confirmed that enzyme activity is significantly increased in
the diabetic retinas as compared with the non-diabetic controls
(Figure 1C).
The above studies showed that diabetes induces increases in
retinal arginase activity and suggested that both isoforms are
upregulated. However, there are numerous sources of arginase
within the retina. To specifically assess the effects of diabetes in
increasing arginase in vascular cells, we isolated retinal vessels
from diabetic and control retinas and performed Western blot
for arginase I and II. Vessels from three groups of six diabetic
and control retinas were isolated by isotonic shock and pooled for
Western blot analysis. The results showed that the retinal vessels
were positive for both isoforms and that arginase I was increased
in the vessels from diabetic mice as compared with the controls
(Figure 1D). Levels of arginase II were similar in vessels from the
diabetic and control mice (Figure 1E).
In order to determine more specifically the potential effects
of diabetes and hyperglycemia on arginase expression/activity in
the vascular endothelium, we performed additional experiments
using retinal EC treated with HG media (25 mM glucose). l-
Arginine hydrolysis assay showed that HG treatment caused a
significant increase in arginase activity (∼30%, Figure 2A). West-
ern blotting showed that both arginase isoforms are expressed
in retinal ECs and that arginase I was increased significantly
in the ECs treated with HG as compared with the control ECs
(Figure 2B). Levels of arginase II were not altered by the HG
treatment (Figure 2C).
DIABETES OR HIGH GLUCOSE-INDUCED REDUCTIONS IN NO
FORMATION ARE RESTORED BY ARGINASE DELETION OR INHIBITION
We next examined the impact of these diabetes- and HG-
induced increases in arginase activity on NO formation. These
experiments used an NO analyzer to evaluate bioavailable NO
vs. total NO products in control and diabetic retina tissue
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FIGURE 1 | Diabetes-induced increases in retinal arginase protein
and activity levels. Mice were rendered diabetic with STZ and
sacrificed after 2 months. (A) Retinal arginase I and II protein distribution
were examined by immunofluorescence imaging. Scale bar=50µM. (B)
Double label of arginase I (green) and cellular retinaldehyde binding
protein (red) was used to assess arginase I distribution in retinal Müller
cells of the wild type and AI+/−AII−/− (KO) retinas. Scale bar= 20µM. (C)
Arginase activity was determined using an assay for urea formation.
Relative levels of arginase I (D) and arginase II (E) protein expression in
retinal vascular cells were determined by Western blot analysis of
isolated retinal vessels (n=6–30) (*p<0.05 compared with the
non-diabetic control).
FIGURE 2 | High glucose-induced increases in arginase protein and
activity levels in retinal vascular EC. Retinal EC (p5–p9) were incubated in
medium (M199+ 0.2%FBS+50µM l-arginine) containing 5.5 mM d-glucose
(NG) or 25 mM d-glucose (HG) for 24 h. (A) Arginase activity in cell lysate was
determined by arginase activity assay (*p<0.05 compared with NG, n=4).
(B,C) Levels of arginase I and II protein were determined by Western blot
analysis (n=3–4) and quantified using ImageJ (*p<0.05 compared with the
NG control).
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extracts and HG-treated retinal ECs. In tissue extracts, the total
amount of NO is represented by the relative amount of tis-
sue nitrate plus nitrite. Nitrite is the final product of NO
auto-oxidation in water or hemoglobin-free media and is an
indicator of the amount of bioavailable NO. On the other
hand, nitrate formation is promoted in the presence of super-
oxide. Thus, an increase in nitrate levels serves as an indica-
tor of NOS uncoupling and nitrosative stress. Analysis of total
nitrate+ nitrite levels showed that STZ-induced diabetes caused
a significant increase in the total NO products compared with
the controls, whereas nitrite levels were significantly decreased
(Figure 3A). To examine the potential role of arginase in these
alterations, parallel studies were performed in double knock-
out mice that lack one copy of the gene for arginase I and
both copies of arginase II (AI+/−AII−/−). The results of this
study showed that the diabetes-induced decrease in nitrite was
prevented in the AI+/−AII−/− mice (Figure 3B), implying the
involvement of arginase in the diabetes-induced reductions in
bioavailable NO.
The effects of STZ-induced diabetes on tissue distribution
of NO were assessed by imaging studies using the NO-specific
indicator dye 4,5-diaminofluorescein-2 diacetate (DAF-2 DA).
DAF-2 DA reacts with NO to form a green fluorescent prod-
uct. Fluorescence intensity measurements showed a significant
decrease in NO levels in diabetic WT compared to control mice
retinas. The DAF-2 DA reaction was predominantly around the
blood vessels and in the inner retina and plexiform layers and in
the photoreceptor outer segment layer (Figure 3C). The signal
was completely blocked by pretreatment with the NOS inhibitor
L-NAME indicating the specificity of the reaction for NO. Further-
more, the diabetes-induced decrease in NO was abrogated in the
AI+/−AII−/− mice, confirming that arginase activity is involved in
reducing bioavailable NO levels in the diabetic retina.
To further assess the potential involvement of arginase in
altering the function of vascular EC NOS during hyperglycemic
conditions, we performed in vitro studies using retinal ECs.
These experiments showed that the HG-induced increase in
arginase activity was accompanied by a significant decrease in
FIGURE 3 | Prevention of diabetes-induced decrease in bioavailable NO
by arginase deletion. Retinas from normoglycemic wild type controls, wild
type diabetic or diabetic knockout mice (KO) were prepared for analysis of NO
formation by using an NO analyzer (A,B) and by DAF-2-DA histochemistry (C).
(A)Total NO content in the diabetic retina was significantly increased
compared with the control as shown by measurement of nitrate+nitrite
levels. (B)The level of bioavailable NO in the wild type diabetic retina was
significantly reduced compared with the controls as shown by measurement
of nitrite levels. The decrease in nitrite levels was blocked in the diabetic KO
mice (*p<0.05, n=4–6). (C) NO formation in situ was determined by
reaction of DAF-2-DA. The DAF-2-DA fluorescent product was significantly
diminished in the wildtype diabetic retina as compared with the non-diabetic
control. This effect was significantly blunted in the diabetic KO retinas.
Pretreatment of the retinal sections with L-NAME (1 mM) markedly reduced
formation of the DAF-2-DA product (*p<0.05 vs. control, #p<0.05 vs.
diabetic, n=4–6, scale bar=50µM).
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NO formation as determined by measurement of nitrite in
the culture medium using an NO analyzer (Figure 4). The
HG-induced decline in NO was blocked by treatment of the
cultures with the highly specific arginase inhibitor BEC, sug-
gesting that HG-induced activation of arginase is involved in
reducing NO production in retinal ECs. All together, these data
support the hypothesis that diabetes reduces nitrite levels in the
retina even though total NO products are increased and imply
that the reduction in nitrite levels is due to increased arginase
activity.
FIGURE 4 | Prevention of high glucose-induced decreases in
bioavailable NO levels in retinal endothelial cells by inhibition of
arginase. Retinal EC (p5–p9) were incubated in medium
(M199+0.2%FBS+50µM l-arginine) containing 5.5 mM d-glucose (NG),
25 mM d-glucose (HG), or 35 mM d-glucose with or without 10µM BEC or
vehicle (Veh, 0.1% saline) for 24 h. The nitrite level in the medium was
determined by NO analyzer (*p<0.05 compared with NG, #p< 0.05 vs.
Veh, n=8–16).
DIABETES OR HIGH GLUCOSE-INDUCED INCREASES IN OXIDATIVE
STRESS LEVELS ARE DIMINISHED BY ARGINASE DELETION/INHIBITION
Increased production of reactive oxygen species (ROS) has been
implicated in the pathogenesis of vascular inflammatory diseases
involving many organs including the retina (27–29). Uncou-
pling of NOS serves as an important mechanism of ROS for-
mation in disease. In the present work, we investigated the
effect of arginase deletion on ROS production in the diabetic
retina. Dihydroethidine (DHE) imaging analysis and quantifi-
cation of superoxide formation in retinal sections show that
superoxide formation was significantly increased in the diabetic
retina (Figure 5). This effect was markedly blunted by treat-
ment with the NOS inhibitor L-NAME and in the AI+/−AII−/−
mice. These results imply that increased arginase activity and
uncoupling of NOS are prominently involved in increasing
oxidative stress in the diabetic retina. Specificity of the reac-
tion for superoxide was demonstrated by near complete inhi-
bition of the signal by superoxide dismutase (SOD, data not
shown).
Tissue culture studies using DHE imaging of retinal ECs also
showed a significant increase in superoxide formation following
3 days of HG treatment (Figure 6). This increase in superoxide for-
mation was significantly inhibited by treatment of the cells with
the arginase inhibitor ABH [2(S)-amino-6-boronohexanoic acid]
or SOD.
DIABETES-INDUCED INCREASES IN LEUKOSTASIS ARE BLOCKED BY
ARGINASE DELETION
An adequate supply of NO is critical for maintaining healthy blood
vessels by maintaining appropriate blood flow and inhibiting
leukocyte attachment to the vessel walls (30). Therefore, diabetes-
induced increases in arginase activity may contribute to vascular
injury by increasing leukostasis. To evaluate whether arginase
FIGURE 5 | Prevention of diabetes-induced increase in oxidative
stress by arginase deletion. DHE imaging was performed using
flash frozen retinal sections from wild type control, wild type
diabetic, and diabetic AI+/−AII−/− mice (KO). Diabetic retinas display
increased production of ROS as compared with the controls. The
increased formation of superoxide was blocked by pretreatment of
the sections with L-NAME (1 mM). Arginase KO also significantly
blunted the diabetes-induced increase in superoxide formation
(*p<0.05 vs. control, #p<0.05 vs. diabetic wild type, n=6, scale
bar=50µM).
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FIGURE 6 | Prevention of high glucose-induced increase in
oxidative stress by arginase inhibition. Retinal EC (p5–p9) were
incubated in medium (M199+0.2%FBS+50µM l-arginine)
containing 5.5 mM d-glucose (NG) or 25 mM d-glucose (HG) for
3 days. DHE imaging shows a significant increase in superoxide
formation in the HG-treated ECs. This effect is markedly blunted by
treatment with the arginase inhibitor ABH (*p<0.05 vs. NG, #<0.05
vs. HG, n=4, scale bar=50µM).
FIGURE 7 | Prevention of diabetes-induced increase in leukocyte
adhesion by arginase deletion.Wild type controls, wild type diabetic or
arginase AI+/−AII−/− (KO) diabetic mice were perfused through left ventricle
with Concanavalin A to label leukocytes attached to the vascular endothelium.
The number of attached leukocytes was significantly increased in the wildtype
diabetic mice as compared to non-diabetic controls and arginase KO
significantly blunted this effect (*p<0.05 vs. control, #p<0.05 vs. diabetic
wildtype, n=5, scale bar=100µM).
activity plays a role in diabetes-induced retinal vascular activa-
tion/injury, we analyzed leukocyte adhesion in the retinal vessels
of WT and AI+/−AII−/− diabetic and control mice. Leukostasis
was assayed by using concanavalin A to label the adherent leuko-
cytes. The data show that the number of adherent leukocytes was
increased significantly in the diabetic retinas compared to con-
trol retinas and this increase is abrogated by deletion of arginase
(Figure 7). This result indicates that increased arginase activity
is critically involved in leukocyte-EC attachment in the diabetic
retina.
In order to further assess the potential role of HG-induced
increases in arginase activity in causing vascular activation and
injury, we examined the effects of HG treatment on expression of
ICAM-1. ICAM-1 is present in low concentrations in the mem-
branes of normal ECs, but the concentrations increase under
conditions of endothelial activation. ICAM-1 is a ligand for the
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FIGURE 8 | Prevention of high glucose-induced increase in
ICAM-1 levels and cell death in retinal ECs by inhibition of
arginase. Retinal EC (p5–p9) were incubated in medium
(M199+0.2%FBS+50µM l-arginine) containing 5.5 mM d-glucose
(NG) or 25 mM d-glucose (HG) for 3 days. (A)Western blotting shows
that the high glucose-induced increase in ICAM-1 levels is prevented
by treatment with the arginase inhibitor ABH. (B,C)TUNEL labeling
shows that the high glucose-induced increase in cell death is
prevented by treatment with ABH (*p<0.05 vs. NG, #<0.05 vs. HG,
n=4, scale bar=50µM).
LFA-1 integrin receptor on leukocytes, which bind to ECs via
ICAM-1/LFA-1. Western blotting for ICAM-1 showed that HG
treatment of retinal ECs caused upregulation of ICAM-1 and
that this effect was abrogated by treatment of the cells with ABH
(Figure 8A).
HIGH GLUCOSE-INDUCED INCREASES IN CELL DEATH ARE REDUCED BY
ARGINASE INHIBITION
We also investigated the potential impact of arginase activation
in retinal EC death under HG conditions. TUNEL assay was per-
formed on cells treated with or without the arginase inhibitor
ABH. As shown in Figure 8, cell death was significantly elevated
in HG-treated BRECs compared to NG controls. This increase
in cell death was prevented by inhibition of arginase, using ABH
treatment (Figures 8B,C). These results demonstrate that arginase
function is involved in HG-induced EC death.
DISCUSSION
Excessive activity of the urea cycle enzyme arginase has recently
emerged as a critical player involved in the development of
numerous vascular disease conditions associated with decreased
NO bioavailability and endothelial dysfunction including dia-
betes, aging, ischemia/reperfusion injury, and hypertension (19,
20, 31–34). Diabetic retinopathy is characterized by progres-
sive vascular damage, beginning with oxidative stress, EC dys-
function, reduced blood flow, and leukostasis (3, 35–37). The
pathology often progresses with formation of acellular capil-
laries, development of diabetic macular edema, and/or vitre-
oretinal neovascularization. Our previous studies have shown
that diabetes-induced increases in arginase activity are involved
in hyperglycemia-induced impairment of retinal endothelial-
dependent vasorelaxation responses (23). Furthermore, the
diabetes-induced increase in arginase activity was accompanied
by an increase in peroxynitrite formation which was blocked
by treatment with ABH [2(S)-amino-6-boronohexanoic acid],
a highly specific inhibitor of arginase activity. In this study,
we determined the impact of arginase activation on signs of
diabetic retinopathy in relation to NO bioavailability, oxidative
stress, and retinal injury. Our results showed that diabetes or
HG-induced increases in arginase expression and activity in
retinal vessels and ECs were associated with decreases in NO,
increases in ROS formation, leukocyte adherence to the vessel
wall, elevated ICAM-1 expression and death of retinal ECs. These
changes were prevented in AI+/−AII−/− mice or by treatment
with arginase inhibitors, indicating the role of arginase in the
pathology.
The effects of diabetes and HG in causing elevation of NOS
expression and activity along with increases in oxidative and
nitrosative stress in retinas of diabetic animals and retinal ECs
are well documented (5, 6, 8, 10, 36). However, this study is the
first to show that levels of bioavailable NO are reduced and that
this effect is prevented by arginase deletion. Much of the pre-
vious work has focused on iNOS as a pathological mediator of
retinopathy, emphasizing the damaging effects of iNOS activity
and formation of peroxynitrite and other oxidants in relation to
vascular EC death and acellular capillary formation in the later
stages of diabetic retinopathy (6, 12, 36). Studies have suggested
that high levels of NO resulting from upregulation of iNOS expres-
sion in retinal glia could be involved in the impairment of retinal
blood flow and responses to light during diabetes (38).
Interpretation of NO-mediated toxicity in retinopathy is com-
plicated by the technical difficulty of measuring NO in biological
samples. Most studies showing increased “NO levels” in retinal
models have used photometric assays to measure total tissue nitrite
levels after reduction of nitrate to nitrite. Given that nitrate for-
mation is favored in the presence of excess superoxide (39), the
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values obtained in such analyses represent relative levels of total
NO produced rather than bioavailable NO. So far, little atten-
tion has been given to the impact of diabetes on bioavailable
NO in retina. However, it is well understood that when the sup-
ply of l-arginine needed for NOS activity is limited, the enzyme
will become uncoupled and will use molecular oxygen to pro-
duce superoxide which combines rapidly with NO to produce the
potent inflammatory and toxic oxidant peroxynitrite. Our current
results indicate that the amount of bioavailable NO is substantially
diminished by HG or diabetes whereas NOS-dependent forma-
tion of superoxide is increased, implying that NOS is uncoupled.
Furthermore, the decline in NO is blocked by inhibiting or knock-
ing out arginase, consistent with the proposed action of arginase
in causing NOS uncoupling. Our study is the first we are aware
of to show that arginase is a key player in diabetes/HG-induced
decreases in bioavailable NO.
Studies in a variety of peripheral tissues have shown that
endothelial dysfunction resulting from impaired NO synthesis
involves arginase. Decreased plasma levels of l-arginine have
been reported in diabetic animals and patients (40, 41). In dia-
betic patients, increased arginase activity has been reported in
penile vessels associated with erectile dysfunction (42, 43). Exper-
iments with diabetic rat aorta and coronary vessels showed that
diabetes-induced impairment of vasorelaxation to acetylcholine
was correlated with increased arginase activity. Treatment of
bovine coronary ECs with HG also increased arginase activity and
diminished NO production, which was normalized by transfection
with arginase I siRNA (19). Here we demonstrate for the first time
that diabetes and HG treatment significantly increased arginase
activity and arginase I protein expression in both retinal vessels
and retinal ECs. Immunolocalization studies showed that the two
isoforms differ in their tissue distribution. Arginase I was local-
ized to the ganglion cell layer and inner nuclear layer and processes
of Muller glial cells. Arginase II was localized to cells of the inner
nuclear layer as well as in the nerve fiber and inner plexiform layers.
It is possible that both arginase isoforms contribute to increased
arginase activity at specific sites within the retina. However the
total amount of arginase II protein was similar in vessels isolated
from diabetic and control retinas.
In our studies, diabetic mice lacking one copy of arginase
I and both copies of arginase II had increased NO levels, less
ROS formation and decreased leukostasis as compared with the
wildtype diabetic mice, which highlights the important role of
arginase expression in diabetes-induced vascular dysfunction. Fur-
ther work is needed to determine the specific isoform involved.
Depending on specific disease conditions, arginase I or arginase
II or both may be involved. Arginase I has been associated with
endothelial dysfunction in aging, diabetes, and ischemia (19, 32,
44). Arginase II activity has been implicated in atherosclerosis (45)
and in retinal neuronal cell degeneration during oxygen-induced
retinopathy (46). Others have shown that arginase I is involved
in altering NOS function in aging rat aortas (31, 44). Previous
studies in coronary ECs have shown that HG-induced increases in
arginase activity can be blocked by transfection of arginase I siRNA
(19). Our previous studies of retinal vascular function in diabetic
mice showed that diabetes-induced retinal vascular dysfunction is
reduced in mice lacking one copy of arginase I (23). In order to
identify the arginase isoform and cellular sources responsible for
specific pathological changes in diabetic retinopathy, additional
studies are needed using cell-specific knockout of arginase I and
arginase II.
In view of the well established role of iNOS in retinal injury
during diabetes (3), the protective effects of arginase blockade in
limiting signs of retinopathy may seem paradoxical. However, it is
important to note that NO has multiple protective actions, includ-
ing blocking platelet aggregation and leukocyte adhesion, inhibit-
ing activation of the proinflammatory transcription factor nuclear
factor (NF)-κB and modifying lipids to form nitroalkenes, which
are anti-inflammatory (47–50). Therefore, under diabetic condi-
tions, inhibition of arginase could limit retinal injury through
increased availability of l-arginine for production of NO. Con-
versely, the beneficial effect of NOS inhibitor treatment in the
diabetic retina may be due in part to blockade of uncoupled NOS.
A study using vessels from old rats has shown that inhibition of
arginase abrogated the aging-induced decrease in eNOS dimer-to-
monomer ratio, an indicator of NOS uncoupling (51) suggesting
that arginase inhibition restores eNOS coupling and increases
bioavailable NO levels. Our present studies indicate that arginase
blockade leads to restoration of bioavailable NO and reductions
in ROS levels in both the diabetic retina and HG-treated retinal
ECs.
We did not investigate the effects of diabetes on NOS expres-
sion and activity in the present study because previous work has
shown that eNOS, iNOS, and nNOS are upregulated in the dia-
betic retina (8, 9, 11, 12). HG treatment of retinal ECs also caused
an increase in expression of eNOS (10). Furthermore, these effects
were accompanied by increases in oxidative stress and peroxyni-
trite formation and inhibiting NOS or scavenging peroxynitrite
reduced oxidative stress and prevented signs of diabetic retinopa-
thy in vivo and in vitro (8, 10). Results of preliminary studies
in which diabetic mice were treated with the arginase inhibitor
ABH showed decreased levels of iNOS protein as compared with
the vehicle-treated diabetic mice (data not shown). Further study
is required to confirm these results and elucidate the underlying
mechanisms.
Further study is also needed to determine the mechanisms by
which diabetes and HG increase arginase activity. Based on our
current studies and previous work of others, multiple factors are
likely to affect arginase activity during diabetes. Increased arginase
activity is associated with inflammatory cytokines and oxidative
stress,both of which are elevated during diabetes (29,52). Evidence
suggests that there is a link between S-nitrosylation and enzyme
activation in specific inflammatory milieus. It has been shown
that iNOS-derived NO directly S-nitrosates and activates arginase
I in ECs stimulated with IFNγ/LPS (53). Peroxynitrite and H2O2
have been shown to increase arginase activity in ECs, through PKC
mediated activation of RhoA/Rho kinase pathway (54, 55).
In conclusion, our data indicate that arginase is a potential
therapeutic target for preserving bioavailability of NO, limiting
oxidative stress, and preventing early signs of diabetic retinopa-
thy. Whereas the role of overactive arginase in peripheral vascular
dysfunction and injury has been a topic of active research, this is
the first time it has been mechanistically linked to retinal vascular
injury in diabetes.
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